(0.32%) 5 116.31 points
(0.31%) 38 357 points
(0.37%) 15 987 points
(-0.97%) $83.04
(5.36%) $2.03
(0.33%) $2 354.90
(0.56%) $27.69
(4.26%) $961.35
(-0.27%) $0.932
(-0.47%) $10.97
(-0.59%) $0.796
(1.63%) $93.37
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 11.39%
@ $29.50
発行日: 15 2月 2024 @ 05:25
リターン: -41.19%
前回のシグナル: 2月 15 - 03:36
前回のシグナル:
リターン: 0.61 %
Live Chart Being Loaded With Signals
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom...
Stats | |
---|---|
本日の出来高 | 280 354 |
平均出来高 | 983 114 |
時価総額 | 864.56M |
EPS | $0 ( 2024-03-07 ) |
次の収益日 | ( $-0.340 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.53 |
ATR14 | $0.0320 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Adage Capital Management, L.p. | Buy | 0 | Common Stock, par value $0.001 per share ("Common Stock") |
2024-04-18 | Cormorant Asset Management, Lp | Buy | 186 521 | Common Stock |
2024-04-18 | Cormorant Asset Management, Lp | Buy | 395 244 | Common Stock |
2024-03-30 | Paggiarino Dario A. | Buy | 14 000 | Common Stock |
2024-03-30 | Paggiarino Dario A. | Buy | 30 570 | Common Stock |
INSIDER POWER |
---|
41.06 |
Last 98 transactions |
Buy: 1 049 923 | Sell: 467 144 |
ボリューム 相関
EyePoint Pharmaceuticals 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
EyePoint Pharmaceuticals 相関 - 通貨/商品
EyePoint Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $46.02M |
総利益: | $41.39M (89.93 %) |
EPS: | $-1.820 |
FY | 2023 |
収益: | $46.02M |
総利益: | $41.39M (89.93 %) |
EPS: | $-1.820 |
FY | 2022 |
収益: | $41.40M |
総利益: | $33.08M (79.89 %) |
EPS: | $-3.34 |
FY | 2021 |
収益: | $36.94M |
総利益: | $28.76M (77.86 %) |
EPS: | $-4.55 |
Financial Reports:
No articles found.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。